Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Altenburg – page 2

22 clinical trials in Altenburg, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Altenburg at a glance
22
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

22 trials in Altenburg

Open in trial search

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.

Ischaemic stroke

Not yet recruiting

Enhanced dual antiplatelet therapy with clopidogrel and acetylsalicylic acid for secondary prevention in patients with mild ischemic stroke

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Technische Universitat Dresden

Cartilage injury

Not yet recruiting

Non‑inferiority study of autologous minced cartilage and autologous cultured chondrocytes in adults with large full‑thickness knee cartilage defects

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Sponsor:Medical Center - University Of Freiburg

Dementia Alzheimer's type

Not yet recruiting

Study on BIIB080 for Patients Aged 50-80 with Mild Cognitive Impairment or Mild Alzheimer's Disease Dementia

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Florbetaben (18F)
  • Sponsor:Biogen Idec Research Limited

Ischaemic stroke

Not yet recruiting

Study on Redasemtide for Adults with Acute Ischemic Stroke Not Eligible for Standard Treatments

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Redasemtide
  • Sponsor:Shionogi B.V.

Ischaemic stroke+2

Not recruiting

Study on Asundexian for Preventing Ischemic Stroke in Adults After a Stroke or High-Risk Mini-Stroke

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Asundexian
  • Sponsor:Bayer AG

Atrial fibrillation

Not recruiting

Study on Milvexian and Apixaban for Preventing Stroke in Patients with Atrial Fibrillation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Andexanet Alfa
  • Sponsor:Janssen Cilag International

Ischaemic stroke

Not recruiting

Study on the Safety and Effectiveness of LT3001 for Patients with Acute Ischemic Stroke

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:LT3001
  • Sponsor:Lumosa Therapeutics Co. Ltd.

Study on Milvexian for Preventing Stroke in Patients with Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Janssen Cilag International

Study on the Safety and Effects of BIIB080 for Patients Aged 50-80 with Mild Cognitive Impairment or Mild Alzheimer's Disease Dementia

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Florbetaben (18F)
  • Sponsor:Biogen Idec Research Limited

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Altenburg

What the registry says about research in the country

01 Stroke Research

Groundbreaking clinical trials focusing on acute ischemic stroke treatment and prevention, including studies of novel therapeutics like sovateltide and asundexian.

  • Acute stroke treatment
  • Stroke prevention
  • Post-stroke care

Multiple studies aim to improve outcomes for patients experiencing stroke or transient ischemic attacks.

02 Neurodegenerative Disorders

Innovative research targeting Alzheimer's Disease, with particular focus on mild cognitive impairment and early-stage dementia treatment approaches.

  • Cognitive function assessment
  • Disease progression monitoring
  • Novel therapeutic interventions

Studies evaluate new treatments to potentially slow or halt cognitive decline in patients aged 50-80 years.

03 Cardiovascular Conditions

Advanced clinical trials examining treatments for atrial fibrillation, including studies of anticoagulation therapies and stroke prevention in cardiac patients.

  • Cardioembolic event prevention
  • Alternative anticoagulation options
  • Cardiac rhythm management

Research focuses on preventing complications in patients unsuitable for traditional treatments.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.